Saltar al contenido
Merck

SAE2002

SARS-COV-2-Spike-RBD epitope (480-499)

≥95% (HPLC), lyophilized powder

Sinónimos:

COVID-19 epitope, Immune response epitope, SARS-COV-2 Spike protein peptide

Iniciar sesión para ver los precios por organización y contrato.

Seleccione un Tamaño


Acerca de este artículo

NACRES:
NA.41
UNSPSC Code:
12352203
Servicio técnico
¿Necesita ayuda? Nuestro equipo de científicos experimentados está aquí para ayudarle.
Permítanos ayudarle
Servicio técnico
¿Necesita ayuda? Nuestro equipo de científicos experimentados está aquí para ayudarle.
Permítanos ayudarle

Nombre del producto

SARS-COV-2-Spike-RBD epitope (480-499), ≥95% (HPLC), lyophilized powder

form

lyophilized powder
solid

species reactivity

viral

UniProt accession no.

storage temp.

−20°C

target post-translational modification

unmodified

Quality Level

Gene Information

SARS coronavirus ... S(43740568)

Application

The peptide may be used in various immunochemical techniques including Immunoblotting and Elisa.

Biochem/physiol Actions

SARS-COV-2-Spike-RBD epitope (480-499) is a synthetic peptide corresponding to the amino acid sequence of Spike RBD region (GeneID: QHD43416.1) in positions 480-499.Peptides derived from the SARS-COV-2-Spike-RBD protein can be recognized by anti-SARS-CoV-2-Spike protein antibodies.
The Spike protein (also known as S protein) is a type I trimeric glycoprotein that is presented on the virion membrane, giving it the appearance of a crown. The protein has two subunits: S1, or bulb, that contains the RBD3-10; and S2, or stalk, responsible for the fusion of the virion with the host cell membrane. The main receptor for SARS-CoV and SARS-CoV-2 on the membrane of the target cells is the Angiotensin 2 Converting Enzyme (ACE2), a metallopeptidase present on the membrane of many cells, including type-I and -II pneumocytes, small intestine enterocytes, kidney proximal tubules cells, the endothelial cells of arteries and veins, and the arterial smooth muscle, among other tissues.15-16

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.Data presented is the available current product information and provided as-is. This product has not been tested or verified in any additional applications, sample types, including any clinical use. Experimental conditions must be empirically derived by the user. Our Antibody Guarantee only covers tested applications stated herein and conditions presented in our product information and is not extended to publications.

General description

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) or (2019-nCoV) is a novel coronavirus that emerged in December 2019 and has since infected millions of people worldwide.1 The Spike protein (also known as S protein) is the most studied of the coronaviruses proteins, since it contains the Receptor-Binding-Domain (RBD) for the ligand on the host cell membrane (the ACE2 protein), and also has epitopes recognized by T and B cells.

Physical form

Supplied as a lyophilized powder.Purity: ≥95% (HPLC)

Preparation Note

Store the product at −20 °C. After initial thawing, it is recommended to store the peptide in working aliquots at −20 °C. Recommended thawing solution: Water.

Clase de almacenamiento

13 - Non Combustible Solids

wgk

WGK 1

flash_point_f

Not applicable

flash_point_c

Not applicable


Elija entre una de las versiones más recientes:

Certificados de análisis (COA)

Lot/Batch Number

¿No ve la versión correcta?

Si necesita una versión concreta, puede buscar un certificado específico por el número de lote.

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Zhixin Liu et al.
Journal of medical virology, 92(6), 595-601 (2020-02-27)
From the beginning of 2002 and 2012, severe respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV) crossed the species barriers to infect humans, causing thousands of infections and hundreds of deaths, respectively. Currently, a novel coronavirus (SARS-CoV-2)
Jun Lan et al.
Nature, 581(7807), 215-220 (2020-04-01)
A new and highly pathogenic coronavirus (severe acute respiratory syndrome coronavirus-2, SARS-CoV-2) caused an outbreak in Wuhan city, Hubei province, China, starting from December 2019 that quickly spread nationwide and to other countries around the world1-3. Here, to better understand the
Xin Zou et al.
Frontiers of medicine, 14(2), 185-192 (2020-03-15)
It has been known that, the novel coronavirus, 2019-nCoV, which is considered similar to SARS-CoV, invades human cells via the receptor angiotensin converting enzyme II (ACE2). Moreover, lung cells that have ACE2 expression may be the main target cells during
Chunyan Yi et al.
Cellular & molecular immunology, 17(6), 621-630 (2020-05-18)
Coronavirus disease 2019 (COVID-19), caused by the novel human coronavirus SARS-CoV-2, is currently a major threat to public health worldwide. The viral spike protein binds the host receptor angiotensin-converting enzyme 2 (ACE2) via the receptor-binding domain (RBD), and thus is
To Sing Fung et al.
Annual review of microbiology, 73, 529-557 (2019-06-22)
Human coronavirus (HCoV) infection causes respiratory diseases with mild to severe outcomes. In the last 15 years, we have witnessed the emergence of two zoonotic, highly pathogenic HCoVs: severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus

Contenido relacionado

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico